- Details
- Deepak Kilari joins Pedro Barata in a discussion on the ORACLE study, which investigates the efficacy of combination systemic therapies in patients with advanced non-clear cell renal cell carcinoma. Dr. Kilari gives an overview of the trial design and shares his hopes and goals for the future of this trial as it continues to expand to more institutions and provide a larger, more robust data set. B...
|
- Details
- Pedro Barata and Nizar Tannir explore updated findings from the CheckMate 214 study, with a focus on sarcomatoid renal cell carcinoma (RCC) patients. They note that despite an improvement in patient outcomes due to nivolumab/ipilimumab (nivo/ipi) treatment, 20% of patients still progress, underscoring the need for ongoing research. The study showed significantly improved response rates and overall...
|
- Details
- Pedro Barata and Hans Hammers discuss a significant paper published in JCO, detailing a phase II trial with nivolumab for treatment of advanced clear cell Renal Cell Carcinoma (RCC). Dr. Hammers attributes the conception of the study to Dr. Mike Atkins and the trials primarily focus on nivolumab's effectiveness in various risk groups. The trials were designed to adopt a risk-adaptive approach, sta...
|
- Details
- In this UroToday Journal Club, Zachary Klaassen reviews the Nature Medicine publication entitled Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nivo and ipi first demonstrated to have a benefit in this setting in the CheckMate 214 trial. However, the vast majority of patients still don't have a response, and...
|
- Details
- Pedro Barata hosts Nizar Tannir to discuss the CANTATA trial for advanced renal cell carcinoma (RCC) treatment. Dr. Tannir explicates the historical progression of RCC therapies, emphasizing the biological implications of glucose metabolism in tumor cells and the need for alternative energy sources such as glutamine. Telaglenastat, a glutaminase inhibitor, offers a potential breakthrough, disrupti...
|
- Details
- In this conversation, Pedro Barata hosts Toni Choueiri to discuss a significant paper that he published on the CheckMate 9ER trial, which has established the combination of cabozantinib-nivolumab as a new standard of care for patients with advanced renal cell carcinoma. The extended follow-up analysis of about 33 months showed statistically significant and clinically relevant progression-free surv...
|
- Details
- Alicia Morgans engages in a discussion with Mohamad Allaf about the PROSPER Study, an ECOG investigation focused on a neoadjuvant perioperative approach to treating high-risk kidney cancer. The conversation delves into the study's rationale and design, exploring the collaboration between medical oncologists and urologists. Dr. Allaf details the premise of the study, highlighting the implementation...
|
- Details
- Alicia Morgans and Naomi Haas discuss the PROSPER Trial, focusing on the study design, results, and insights into kidney cancer treatment. The trial began from a collaboration at the Prostate Cancer Foundation meeting, leading to a two-arm study of 804 patients, exploring the effects of nivolumab preoperatively followed by surgery and adjuvant therapy, versus surgery alone. Unfortunately, the prim...
|
- Details
- Sarmad Sadeghi and Pedro Barata discuss the results of a randomized Phase II that explored OX40in combination with axitinib in patients with renal cell carcinoma. Patients in the trial had progressive disease after receiving immunotherapy with the usual PD-1/PD-L1 antibodies. The primary endpoint was progression-free survival. Dr. Sadeghi describes the rationale for the trial design, why the trial...
|
- Details
- Andrea Apolo, Pavlos Msaouel, and Petros Grivas discuss findings and recommendations shared during an ASCO presentation on clinical trial endpoints in the adjuvant setting for RCC kidney cancer and urothelial cancer. The conversation touches on trial design and efficacy, as well as concerns about treatment burden, toxicity, cost, and survival benefit. Patient advocacy and patient-specific issues r...
|
